<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03803605</url>
  </required_header>
  <id_info>
    <org_study_id>18-1217</org_study_id>
    <secondary_id>U01AI117844</secondary_id>
    <nct_id>NCT03803605</nct_id>
  </id_info>
  <brief_title>Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons</brief_title>
  <official_title>IGHID 11802 - Combination Therapy With the Novel Clearance Modality (VRC07-523LS) and the Latency Reversal Agent (Vorinostat) to Reduce the Frequency of Latent, Resting CD4+ T Cell Infection (The VOR-07 Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adult participants (18-64 years old) with HIV-1 Infection on ART with a CD4 T cell count ≥&#xD;
      350 cells/mm3 and viral suppression for ≥ 24 months will be enrolled on this study.&#xD;
      Participants will receive two series of combination therapy consisting of one (1) intravenous&#xD;
      (IV) dose of VRC-HIVMAB075-00-AB (VRC07-523LS) followed by 10 oral (PO) doses of Vorinostat&#xD;
      (VOR) taken every 72 hours. Each series will last approximately 1 month and the two series&#xD;
      will be separated by at least one month. Combination ART is maintained throughout the study.&#xD;
      Participants will be on this study for approximately 28 weeks (or about 7 months).&#xD;
&#xD;
      The purpose of this study is to:&#xD;
&#xD;
        -  Evaluate the safety of two series of a VRC07-523LS infusion followed by multiple oral&#xD;
           doses of VOR&#xD;
&#xD;
        -  Determine if combining VRC07-523LS and VOR can have an impact on non-active HIV virus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I, single-site, open-label study to evaluate the effects of VOR given in&#xD;
      combination with VRC07-523LS on persistent HIV-1 Infection in HIV-infected individuals&#xD;
      suppressed on ART.&#xD;
&#xD;
      The investigators hypothesize that combination therapy with VRC07-523LS and VOR will be safe&#xD;
      and well-tolerated by HIV-1-infected participants suppressed on ART.&#xD;
&#xD;
      In Step 1, all participants will undergo study screening and enrollment. Participants will&#xD;
      complete a baseline Leukapheresis (#1). In order to advance to Step 2, participants must be&#xD;
      found to have a baseline measurement of the frequency of resting CD4 T cell infection ≥ 0.3&#xD;
      infectious units per million (IUPM) determined by Quantitative Viral Outgrowth Assay (QVOA)&#xD;
      (lower limit of detection is 0.03 IUPM), as a further decrease from this low frequency of&#xD;
      infection cannot be definitively measured given the QVOA assay threshold.&#xD;
&#xD;
      These criteria assure that eligible enrolled participants will have a measurable endpoint,&#xD;
      thus decreasing risk of study participation for participants who would not have a measurable&#xD;
      outcome.&#xD;
&#xD;
      Participants progressing to Steps 2 and 3 will receive two series of a single VRC07-523LS&#xD;
      infusion followed by multiple doses of VOR.&#xD;
&#xD;
      In the first series (Step 2), participants will receive one VRC07-523LS 40 mg/kg infusion&#xD;
      (infusion #1) on Day 0 followed by the 1st dose of VOR 400 mg PO taken at home on Day 2.&#xD;
      Participants will take VOR 400 mg PO every 72 hours for a total of 10 doses.&#xD;
&#xD;
      In the second series (Step 3), participants will receive one VRC07-523LS 40 mg/kg infusion&#xD;
      (infusion #2) on Day 60 followed by the 1st (of the 2nd series of VOR) dose of VOR 400 mg PO&#xD;
      on Day 62. As in the previous Step, participants will take VOR 400 mg PO every 72 hours for a&#xD;
      total of 10 doses.&#xD;
&#xD;
      Step 4 consists of 2 visits. The post-study treatment leukapheresis (#2) will be completed 5&#xD;
      - 8 weeks after the 2nd VRC07-523LS infusion. The End of Study Visit (EOS) will be scheduled&#xD;
      to 2 - 4 weeks following the final leukapheresis (#2) visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 12, 2019</start_date>
  <completion_date type="Actual">January 28, 2021</completion_date>
  <primary_completion_date type="Actual">January 28, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Arm: All participants will receive combination therapy consisting of VRC07-523LS and Vorinostat.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Participants With a Grade 3 or Higher Treatment-Related Adverse Event (AE)</measure>
    <time_frame>First day of study treatment through end of study, a total of approximately 36 weeks</time_frame>
    <description>The DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017 was used to measure safety where Grade 3 is defined as severe and Grade 4 is defined as potentially life-threatening. Treatment-Related AEs assessments are considered related to study product as possible, probable, or definite as defined in the protocol.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>VRC07-523LS + Vorinostat (VOR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive two series of combination therapy consisting of one (1) intravenous (IV) dose of VRC-HIVMAB075-00-AB (VRC07-523LS) followed by 10 oral (PO) doses of Vorinostat (VOR) taken every 72 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VRC07-523LS</intervention_name>
    <description>VRC07-523LS 40 mg/kg administered intravenously per series (total of 2 infusions administered)</description>
    <arm_group_label>VRC07-523LS + Vorinostat (VOR)</arm_group_label>
    <other_name>VRC-HIVMAB075-00-AB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vorinostat (VOR)</intervention_name>
    <description>Vorinostat 400 mg administered orally every 72 hours for 10 doses per series (A total of 20 400-mg doses administered)</description>
    <arm_group_label>VRC07-523LS + Vorinostat (VOR)</arm_group_label>
    <other_name>Zolinza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ≥ 18 years and &lt; 65 years of age&#xD;
&#xD;
          2. Ability and willingness of participant to give written informed consent. Note: Due to&#xD;
             the lack of foreseeable benefit to study participants, mentally incompetent&#xD;
             participants will not be enrolled.&#xD;
&#xD;
          3. HIV infection documented by any licensed rapid HIV test or HIV enzyme or&#xD;
             chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and&#xD;
             confirmed by a licensed Western blot or a second antibody test by a method other than&#xD;
             the initial rapid HIV and/or E/CIA, or by HIV-1 antigen, plasma HIV-1 RNA viral assay.&#xD;
&#xD;
             A reactive initial rapid test should be confirmed by either another type of rapid&#xD;
             assay or an E/CIA that is based on a different antigen preparation and/or different&#xD;
             test principle (e.g., indirect versus competitive), or a Western blot or a plasma&#xD;
             HIV-1 RNA viral load.&#xD;
&#xD;
          4. On continuous antiretroviral therapy (ART defined below under Inclusion Criterion #5)&#xD;
             for at least 24 months prior to screening.&#xD;
&#xD;
             Note: Continuous ART prior to screening is defined as not missing more than 9 total&#xD;
             days in the 3 months prior to screening.&#xD;
&#xD;
          5. Permitted regimens include:&#xD;
&#xD;
               1. At least 3 ART agents (not counting ritonavir if less than a 200 mg total daily&#xD;
                  dose or cobicistat as one of the agents)&#xD;
&#xD;
                  Note: One of the agents must include an integrase inhibitor, NNRTI&#xD;
                  (Non-Nucleoside Reverse Transcriptase Inhibitors), or a boosted-PI (protease&#xD;
                  inhibitor).&#xD;
&#xD;
                  OR&#xD;
&#xD;
               2. Two ART agents in which one of the agents is either a boosted PI or an integrase&#xD;
                  inhibitor.&#xD;
&#xD;
             Note: Other fully suppressive antiretroviral combinations will be considered on a&#xD;
             case-by-case basis.&#xD;
&#xD;
             Note: Prior changes in, or elimination of, medications for easier dosing schedule,&#xD;
             intolerance, toxicity, improved side effect profile or within a drug class are&#xD;
             permitted if an alternative suppressive regimen was maintained but not within 30 days&#xD;
             prior to screening.&#xD;
&#xD;
             Note: Changes in drug formulation or dose are allowed (e.g., tenofovir disoproxil&#xD;
             fumarate (TDF) to tenofovir alafenamide (TAF), ritonavir to cobicistat, or separate&#xD;
             ART agent dosing to fixed-dose combination), but none within 30 days prior to&#xD;
             screening.&#xD;
&#xD;
          6. Ability and willingness of participant to continue ART throughout the study.&#xD;
&#xD;
          7. Able and willing to adhere to protocol therapy, schedule, and is judged adherent to&#xD;
             antiretroviral therapy.&#xD;
&#xD;
          8. Plasma HIV-1 RNA &lt;50 copies/mL at 3 time points in the previous 24 months prior to&#xD;
             screening and never ≥50 copies/mL on 2 consecutive time points in the last 24 months.&#xD;
&#xD;
             Note: The documented plasma HIV-1 RNA must be performed by any US laboratory that has&#xD;
             a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent.&#xD;
&#xD;
          9. At least 1 documented plasma HIV-1 RNA result &lt;50 copies/mL ≥24 months but ≤ 36 months&#xD;
             prior to screening.&#xD;
&#xD;
         10. Plasma HIV-1 RNA level &lt;50 copies/mL on an FDA-approved HIV RNA assay at screening,&#xD;
             performed at US CLIA Certified Laboratory (or its equivalent).&#xD;
&#xD;
         11. CD4 cell count ≥ 350 cells/mm³ obtained within 90 days prior to study entry, performed&#xD;
             at any US CLIA Certified Laboratory (or its equivalent).&#xD;
&#xD;
         12. Hepatitis C (HCV) antibody negative result within 60 days prior to study entry or, if&#xD;
             the participant is HCV antibody positive, a negative HCV RNA within 60 days prior to&#xD;
             study entry .&#xD;
&#xD;
         13. Hepatitis B surface antigen (HBsAg) negative within 60 days prior to study entry.&#xD;
&#xD;
         14. Interferon-gamma release assay (IGRA) for tuberculosis (TB) with negative results&#xD;
             within 60 days prior to study entry.&#xD;
&#xD;
             Note: Participants with a prior positive TB IGRA and documented evidence of completed&#xD;
             prophylaxis treatment may enroll in the study and do not need to undergo IGRA at&#xD;
             screening. Participants with a prior positive IGRA who have not completed prophylaxis&#xD;
             treatment will be excluded.&#xD;
&#xD;
         15. Men and women who are not of reproductive potential (see below) are eligible without&#xD;
             requiring the use of contraceptives. Acceptable documentation of sterilization and&#xD;
             menopause is specified below.&#xD;
&#xD;
             a) Written or oral documentation communicated by clinician or clinician's staff of one&#xD;
             of the following:&#xD;
&#xD;
               1. Physician report/letter&#xD;
&#xD;
               2. Operative report or other source documentation in the patient record (a&#xD;
                  laboratory report of azoospermia is required to document successful vasectomy in&#xD;
                  any partner assigned male sex at birth, hysterectomy, oophorectomy, non-surgical&#xD;
                  permanent sterilization, or tubal ligation.)&#xD;
&#xD;
               3. Discharge summary&#xD;
&#xD;
               4. Documented or participant-reported absence of a period for ≥ one year must be&#xD;
                  confirmed with Follicle stimulating hormone-release factor (FSH) measurement&#xD;
                  elevated into the menopausal range as established by the reporting laboratory.&#xD;
&#xD;
         16. All participants must agree not to participate in a conception process (e.g., active&#xD;
             attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization,&#xD;
             egg donation) while on study and for 4 months after their last infusion.&#xD;
&#xD;
         17. All men participating in sexual activity that could lead to pregnancy must agree to&#xD;
             consistently use at least one of the following forms of birth control for at least 21&#xD;
             days prior to Visit 3 and for 4 months after their last infusion:&#xD;
&#xD;
             a) Condoms (male or female) with or without a spermicidal agent b) Diaphragm or&#xD;
             cervical cap with spermicide c) Intrauterine device (IUD) d) Tubal ligation e)&#xD;
             Hormone-based contraceptive f) Successful vasectomy&#xD;
&#xD;
             Note: For female partners who are receiving ritonavir or cobicistat, estrogen-based&#xD;
             contraceptives are not reliable and an alternative method should be suggested.&#xD;
&#xD;
         18. Ability and willingness to provide adequate locator information.&#xD;
&#xD;
         19. Ability and willingness to communicate effectively with study personnel; considered&#xD;
             reliable, willing, and cooperative in terms of compliance with the protocol&#xD;
             requirements.&#xD;
&#xD;
         20. Adequate vascular access for infusion and leukapheresis.&#xD;
&#xD;
         21. Able to swallow pills without difficulty.&#xD;
&#xD;
         22. Agrees not to enroll on another study of an investigational research agent during the&#xD;
             study period.&#xD;
&#xD;
             Note: Investigational research agent is defined as any unlicensed investigational drug&#xD;
             not yet approved by the FDA for intended use in humans.&#xD;
&#xD;
         23. Adequate organ function as indicated by the following laboratory values:&#xD;
&#xD;
        Hematological: Absolute neutrophil count (ANC) ≥1,500 /mm^3; Platelets ≥125,000 / mm^3;&#xD;
        Hemoglobin ≥ 13 g/dL (male) and ≥ 11 g/dL (females)&#xD;
&#xD;
        Coagulation: Prothrombin Time or International Normalized Ratio (INR) ≤1.5x upper limit of&#xD;
        normal (ULN)&#xD;
&#xD;
        Chemistries: K+ levels - Within normal limits; Mg++ levels ≥ 1.2 milliequivalents/L but&#xD;
        &lt;1.5 x ULN; Glucose - Screening serum glucose ≤ Grade 1 (fasting or non- fasting); Albumin&#xD;
        ≥ 3.3 g/dL&#xD;
&#xD;
        Renal: Creatinine clearance determined by the chronic kidney disease (CKD)-Epi equation&#xD;
&#xD;
        Hepatic: Serum total bilirubin - Total bilirubin &lt; 1.5 X ULN. If total bilirubin is&#xD;
        elevated, direct bilirubin must be &lt; 2 times the ULN range.&#xD;
&#xD;
        Note: If participant is on an atazanavir-containing therapy, then a direct bilirubin should&#xD;
        be measured instead of the total bilirubin and must be ≤ 1.0 mg/dL.; aspartate&#xD;
        aminotransferase (AST, SGOT) and alanine transaminase (ALT, SGPT) ≤ 1.25 X ULN; Alkaline&#xD;
        Phosphatase ≤ 2.0 X ULN; Lipase &lt; 1.6 X ULN; Urinalysis: Urine Protein - Negative or trace&#xD;
        allowed ULN = upper limit of normal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known allergy or sensitivity to components of VOR&#xD;
&#xD;
          2. Serious adverse reactions to VRC07-523LS formulation components, VRC01 or VRC01LS,&#xD;
             including history of anaphylaxis and related symptoms such as hives, respiratory&#xD;
             difficulties, angioedema, and/or abdominal pain.&#xD;
&#xD;
          3. Women without documentation of an FSH level indicating menopause, hysterectomy or&#xD;
             bilateral oophorectomy, bilateral tubal ligation, or non-surgical sterilization.&#xD;
&#xD;
          4. Receipt of compounds with histone deacetylase (HDAC) inhibitor-like activity, such as&#xD;
             valproic acid within 30 days prior to screening. Potential participants may screen&#xD;
             after a 30-day washout period.&#xD;
&#xD;
          5. Any investigational research agent within 30 days before study entry.&#xD;
&#xD;
             Note: Co-enrollment in observational only studies is permitted.&#xD;
&#xD;
             Note: Co-enrollment in other studies using FDA approved medication that are not&#xD;
             otherwise listed as prohibited will be evaluated by the study PI and permitted on a&#xD;
             case by case basis.&#xD;
&#xD;
          6. Plasma HIV RNA ≥150 copies/mL in the 6 months prior to screening.&#xD;
&#xD;
          7. Weight &gt; 115 kg&#xD;
&#xD;
          8. Untreated syphilis infection (defined as a positive rapid plasma reagin (RPR) without&#xD;
             clear documentation of treatment).&#xD;
&#xD;
             Note: In cases of untreated syphilis, participant may rescreen following documentation&#xD;
             of adequate treatment of syphilis&#xD;
&#xD;
          9. Current treatment for HCV with antiviral therapy or participants who have received HCV&#xD;
             treatment within 6 months prior to screening.&#xD;
&#xD;
         10. Use of any of the following within 90 days prior to entry: immunosuppressive,&#xD;
             immunomodulatory, cytokine, or growth stimulating factors such as systemic&#xD;
             corticosteroids, cyclosporine, methotrexate, azathioprine, anti-CD25 antibody,&#xD;
             interferon (IFN), interleukin-2 (IL-2).&#xD;
&#xD;
             Not Exclusionary: [1] corticosteroid nasal spray; [2] inhaled corticosteroids; [3]&#xD;
             topical steroids for mild, uncomplicated dermatitis; or [4] a single course of oral&#xD;
             /parental prednisone or equivalent at doses &lt;2mg/kg/day and length of therapy &lt;11 days&#xD;
             with completion at least 30 days prior to enrollment.&#xD;
&#xD;
         11. Current use of Coumadin, warfarin, or other Coumadin derivative anticoagulants.&#xD;
&#xD;
         12. Prior receipt of HIV immunotherapy within 6 months prior to screening.&#xD;
&#xD;
         13. Prior receipt of more than three doses of Vorinostat.&#xD;
&#xD;
         14. Prior receipt of humanized or human monoclonal antibodies (mAbs) within 2 months prior&#xD;
             to screening, whether licensed or investigational, will have eligibility determined by&#xD;
             the study PI on a case-by-case basis.&#xD;
&#xD;
         15. Received any infusion blood product, immune globulin, or hematopoietic growth factors&#xD;
             within 90 days prior to study entry.&#xD;
&#xD;
         16. Pregnancy or breast-feeding.&#xD;
&#xD;
         17. History or other evidence of severe illness, malignancy, immunodeficiency other than&#xD;
             HIV, or any other condition that would make the participant unsuitable for the study&#xD;
             in the opinion of the investigator, for at least 90 days prior to screening.&#xD;
&#xD;
         18. History of autoimmune disease&#xD;
&#xD;
             Not exclusionary: Persons with mild, stable, and uncomplicated autoimmune disease that&#xD;
             does not require immunosuppressive medication and that, in the judgement of the site&#xD;
             investigator (or designee), is likely not subject to exacerbation and likely not to&#xD;
             complicate adverse event (AE) assessments.&#xD;
&#xD;
         19. Use of topical steroids over a total area exceeding 15 cm-2 within 30 days prior to&#xD;
             Screening.&#xD;
&#xD;
         20. Treatment for an active AIDS-defining opportunistic infection within 90 days prior to&#xD;
             Screening.&#xD;
&#xD;
         21. History of malignancy within the last 5 years.&#xD;
&#xD;
             Note: A history of non-melanoma skin cancer (e.g., basal cell carcinoma or squamous&#xD;
             cell skin cancer) is not exclusionary with documentation of complete resection at&#xD;
             least 3 months prior to enrollment).&#xD;
&#xD;
         22. Compulsorily detained (involuntarily incarcerated) for treatment of either a&#xD;
             psychiatric illness or a physical illness, e.g., infectious disease.&#xD;
&#xD;
         23. Known psychiatric, medical, occupational, or substance abuse disorders that would&#xD;
             interfere with participant's ability to fully cooperate with the requirements of the&#xD;
             trial as assessed by the study investigator (or designee).&#xD;
&#xD;
             Specifically exclusionary: [1] recent psychosis; [2] ongoing risk for suicide; or [3]&#xD;
             recent history of suicide attempt or gesture.&#xD;
&#xD;
         24. History or other clinical evidence of a significant medical condition that includes&#xD;
             but is not limited to:&#xD;
&#xD;
             a) A process that would affect the immune response b) A process that would require&#xD;
             medication that affects the immune response c) Any contraindication to repeated&#xD;
             injections, infusions, or blood draws d) A condition or process (e.g., chronic&#xD;
             urticarial or recent injection or infusion with evidence of residual inflammation) for&#xD;
             which signs and symptoms could be confused with reactions to the study product&#xD;
&#xD;
         25. Current anti-tuberculosis therapy&#xD;
&#xD;
         26. Diabetes Mellitus type 1&#xD;
&#xD;
             Note: Individuals with type 2 diabetes who meet inclusion criteria for glucose&#xD;
             (Inclusion Criterion #23) are not excluded.&#xD;
&#xD;
         27. History of coronary artery disease, congestive heart failure, or cardiac arrhythmia&#xD;
             requiring current treatment prior to study screening.&#xD;
&#xD;
         28. Hypertension - Exclude for blood pressure consistently &gt;150 mm Hg systolic and &gt;100 mm&#xD;
             Hg diastolic.&#xD;
&#xD;
             Note: Elevated BP occurring during research leukapheresis procedures completed within&#xD;
             the past 12 months are excluded from this requirement. Acceptable isolated elevations&#xD;
             must be noted as acceptable and signed by study PI or designee.&#xD;
&#xD;
         29. Unstable asthma (e.g., sudden acute attacks occurring without an obvious trigger) or&#xD;
             either of the following in the past 12 months:&#xD;
&#xD;
               1. &gt;1 exacerbation of symptoms treated with oral/parental corticosteroids;&#xD;
&#xD;
               2. Emergency care, urgent care, hospitalization, or intubation for asthma.&#xD;
&#xD;
         30. Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or&#xD;
             platelet disorder requiring special precautions)&#xD;
&#xD;
         31. Seizure disorder: History of seizure(s) within past three years or use of medications&#xD;
             used to prevent or treat seizure(s) at any time within the past 3 years.&#xD;
&#xD;
         32. History of asplenia - absence of normal spleen function as indicated by:&#xD;
&#xD;
               1. Splenectomy&#xD;
&#xD;
               2. Sickle cell disease&#xD;
&#xD;
         33. History of hereditary angioedema, acquired angioedema, or idiopathic angioedema.&#xD;
&#xD;
         34. Prisoner recruitment and participation is not permitted.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cindy L Gay, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC-Chapel Hill</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David M Margolis, MD</last_name>
    <role>Study Director</role>
    <affiliation>UNC-Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina Health Care</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 10, 2019</study_first_submitted>
  <study_first_submitted_qc>January 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2019</study_first_posted>
  <results_first_submitted>November 4, 2021</results_first_submitted>
  <results_first_submitted_qc>November 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">December 2, 2021</results_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VRC07-523LS</keyword>
  <keyword>Vorinostat</keyword>
  <keyword>HIV-1</keyword>
  <keyword>Suppressed</keyword>
  <keyword>Latency</keyword>
  <keyword>Reversal</keyword>
  <keyword>Novel</keyword>
  <keyword>Monoclonal</keyword>
  <keyword>Agent</keyword>
  <keyword>Antibody</keyword>
  <keyword>Frequency</keyword>
  <keyword>T Cell</keyword>
  <keyword>Infection</keyword>
  <keyword>ART</keyword>
  <keyword>Resting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 18, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT03803605/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants meeting the following advancement criteria in Step 1: a frequency of resting CD4+ T cell infection (RCI) &gt;0.30 per million cells proceeded to Step 2 and received the study intervention.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>VRC07-523LS + Vorinostat (VOR)</title>
          <description>Participants will receive two series of combination therapy consisting of one (1) intravenous (IV) dose of VRC-HIVMAB075-00-AB (VRC07-523LS) followed by 10 oral (PO) doses of Vorinostat (VOR) taken every 72 hours.&#xD;
VRC07-523LS: VRC07-523LS 40 mg/kg administered intravenously per series (total of 2 infusions administered)&#xD;
Vorinostat (VOR): Vorinostat 400 mg administered orally every 72 hours for 10 doses per series (A total of 20 400-mg doses administered)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Step 1: Participants With an RCI Measurement &gt; 0.30 Per Million Cells</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Steps 2-4: Participants Receiving Study Intervention</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VRC07-523LS + Vorinostat (VOR)</title>
          <description>Participants will receive two series of combination therapy consisting of one (1) intravenous (IV) dose of VRC-HIVMAB075-00-AB (VRC07-523LS) followed by 10 oral (PO) doses of Vorinostat (VOR) taken every 72 hours.&#xD;
VRC07-523LS: VRC07-523LS 40 mg/kg administered intravenously per series (total of 2 infusions administered)&#xD;
Vorinostat (VOR): Vorinostat 400 mg administered orally every 72 hours for 10 doses per series (A total of 20 400-mg doses administered)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" lower_limit="26" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants With a Grade 3 or Higher Treatment-Related Adverse Event (AE)</title>
        <description>The DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017 was used to measure safety where Grade 3 is defined as severe and Grade 4 is defined as potentially life-threatening. Treatment-Related AEs assessments are considered related to study product as possible, probable, or definite as defined in the protocol.</description>
        <time_frame>First day of study treatment through end of study, a total of approximately 36 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VRC07-523LS + Vorinostat (VOR)</title>
            <description>Participants will receive two series of combination therapy consisting of one (1) intravenous (IV) dose of VRC-HIVMAB075-00-AB (VRC07-523LS) followed by 10 oral (PO) doses of Vorinostat (VOR) taken every 72 hours.&#xD;
VRC07-523LS: VRC07-523LS 40 mg/kg administered intravenously per series (total of 2 infusions administered)&#xD;
Vorinostat (VOR): Vorinostat 400 mg administered orally every 72 hours for 10 doses per series (A total of 20 400-mg doses administered)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With a Grade 3 or Higher Treatment-Related Adverse Event (AE)</title>
          <description>The DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017 was used to measure safety where Grade 3 is defined as severe and Grade 4 is defined as potentially life-threatening. Treatment-Related AEs assessments are considered related to study product as possible, probable, or definite as defined in the protocol.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For all participants (n=15): from the signing of informed consent through completion of Baseline leukapheresis (Visit 2), approximately 10 weeks. For qualifying participants who advanced to Step 2 (n=8) and initiated treatment (Visit 3) through end of study (Visit 13) an additional 26 weeks. A combined overall total of 36 weeks for intervention-treated participants.</time_frame>
      <desc>Solicited adverse events were collected using diaries for 72 hours following each infusion of VRC07-523LS. For reactogenicity assessment, participants recorded local and systemic pre-defined adverse events. Unsolicited adverse events were actively assessed by study staff at each intervention.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Enrolled Participants Completing Step 1 (Visits 1 and 2)</title>
          <description>Participants meeting enrollment criteria who completed a Baseline leukapheresis procedure.</description>
        </group>
        <group group_id="E2">
          <title>Participants Receiving VRC07-523LS + Vorinostat (VOR) (Step 2/Visits 3-13)</title>
          <description>Participants with a Baseline RCI &gt; 0.30 per million cells who received two series of combination therapy consisting of one (1) intravenous (IV) dose of VRC-HIVMAB075-00-AB (VRC07-523LS) followed by 10 oral (PO) doses of Vorinostat (VOR) taken every 72 hours.&#xD;
VRC07-523LS: VRC07-523LS 40 mg/kg administered intravenously per series (total of 2 infusions administered)&#xD;
Vorinostat (VOR): Vorinostat 400 mg administered orally every 72 hours for 10 doses per series (A total of 20 400-mg doses administered)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Tissue infiltration</sub_title>
                <description>During leukapheresis procedure</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vessel puncture site bruise</sub_title>
                <description>During leukapheresis procedure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vessel puncture site swelling</sub_title>
                <description>During leukapheresis procedure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural hypertension</sub_title>
                <description>During leukapheresis procedure</description>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="15"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood HIV RNA increased</sub_title>
                <description>Viral load &gt;50 copies/mL (160 copies/mL)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood pressure systolic increased</sub_title>
                <description>During infusion procedure</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Athralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="6" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Skin discoloration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Cynthia Gay, MD, MPH</name_or_title>
      <organization>University of North Carolina at Chapel Hill</organization>
      <phone>919-966-2537</phone>
      <email>cynthia_gay@med.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03803605
org study id: 18-1217
secondary id: U01AI117844
nct id: NCT03803605
lead sponsor: 
collaborator: 
has dmc: Yes
is fda regulated drug: Yes
is fda regulated device: No
Adult participants (18-64 years old) with HIV-1 Infection on ART with a CD4 T cell count ≥
      350 cells/mm3 and viral suppression for ≥ 24 months will be enrolled on this study.
      Participants will receive two series of combination therapy consisting of one (1) intravenous
      (IV) dose of VRC-HIVMAB075-00-AB (VRC07-523LS) followed by 10 oral (PO) doses of Vorinostat
      (VOR) taken every 72 hours. Each series will last approximately 1 month and the two series
      will be separated by at least one month. Combination ART is maintained throughout the study.
      Participants will be on this study for approximately 28 weeks (or about 7 months).

      The purpose of this study is to:

        -  Evaluate the safety of two series of a VRC07-523LS infusion followed by multiple oral
           doses of VOR

        -  Determine if combining VRC07-523LS and VOR can have an impact on non-active HIV virus.
This is a phase I, single-site, open-label study to evaluate the effects of VOR given in
      combination with VRC07-523LS on persistent HIV-1 Infection in HIV-infected individuals
      suppressed on ART.

      The investigators hypothesize that combination therapy with VRC07-523LS and VOR will be safe
      and well-tolerated by HIV-1-infected participants suppressed on ART.

      In Step 1, all participants will undergo study screening and enrollment. Participants will
      complete a baseline Leukapheresis (#1). In order to advance to Step 2, participants must be
      found to have a baseline measurement of the frequency of resting CD4 T cell infection ≥ 0.3
      infectious units per million (IUPM) determined by Quantitative Viral Outgrowth Assay (QVOA)
      (lower limit of detection is 0.03 IUPM), as a further decrease from this low frequency of
      infection cannot be definitively measured given the QVOA assay threshold.

      These criteria assure that eligible enrolled participants will have a measurable endpoint,
      thus decreasing risk of study participation for participants who would not have a measurable
      outcome.

      Participants progressing to Steps 2 and 3 will receive two series of a single VRC07-523LS
      infusion followed by multiple doses of VOR.

      In the first series (Step 2), participants will receive one VRC07-523LS 40 mg/kg infusion
      (infusion #1) on Day 0 followed by the 1st dose of VOR 400 mg PO taken at home on Day 2.
      Participants will take VOR 400 mg PO every 72 hours for a total of 10 doses.

      In the second series (Step 3), participants will receive one VRC07-523LS 40 mg/kg infusion
      (infusion #2) on Day 60 followed by the 1st (of the 2nd series of VOR) dose of VOR 400 mg PO
      on Day 62. As in the previous Step, participants will take VOR 400 mg PO every 72 hours for a
      total of 10 doses.

      Step 4 consists of 2 visits. The post-study treatment leukapheresis (#2) will be completed 5
      - 8 weeks after the 2nd VRC07-523LS infusion. The End of Study Visit (EOS) will be scheduled
      to 2 - 4 weeks following the final leukapheresis (#2) visit.
allocation: N/A
intervention model: Single Group Assignment
intervention model description: Single Arm: All participants will receive combination therapy consisting of VRC07-523LS and Vorinostat.
primary purpose: Prevention
masking: None (Open Label)
measure: Percent of Participants With a Grade 3 or Higher Treatment-Related Adverse Event (AE)
time frame: First day of study treatment through end of study, a total of approximately 36 weeks
description: The DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017 was used to measure safety where Grade 3 is defined as severe and Grade 4 is defined as potentially life-threatening. Treatment-Related AEs assessments are considered related to study product as possible, probable, or definite as defined in the protocol.
arm group label: VRC07-523LS + Vorinostat (VOR)
arm group type: Experimental
description: Participants will receive two series of combination therapy consisting of one (1) intravenous (IV) dose of VRC-HIVMAB075-00-AB (VRC07-523LS) followed by 10 oral (PO) doses of Vorinostat (VOR) taken every 72 hours.
intervention type: Biological
intervention name: VRC07-523LS
description: VRC07-523LS 40 mg/kg administered intravenously per series (total of 2 infusions administered)
arm group label: VRC07-523LS + Vorinostat (VOR)
other name: VRC-HIVMAB075-00-AB
intervention type: Drug
intervention name: Vorinostat (VOR)
description: Vorinostat 400 mg administered orally every 72 hours for 10 doses per series (A total of 20 400-mg doses administered)
arm group label: VRC07-523LS + Vorinostat (VOR)
other name: Zolinza
criteria: 
gender: All
minimum age: 18 Years
maximum age: 64 Years
healthy volunteers: No
last name: Cindy L Gay, MD, MPH
role: Principal Investigator
affiliation: UNC-Chapel Hill
last name: David M Margolis, MD
role: Study Director
affiliation: UNC-Chapel Hill
facility: 
country: United States
responsible party type: Sponsor
mesh term: Infections
mesh term: Vorinostat
sharing ipd: No
provided document: 
participant flow: 
baseline: 
outcome list: 
reported events: 
certain agreements: 
point of contact: 